Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth

Oncogene

Volumn 28, Issue 42, 2009, Pages 3689-3701

  Zhao, Y H ^a,b   Zhou, M ^a   Liu, H ^a   Ding, Y ^a   Khong, H T ^a   Yu, D ^c   Fodstad, O ^a,d   Tan, M ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Breast cancer; ErbB2; Glycolysis; HSF1; LDH A; Warburg effect

Indexed keywords

DEOXYGLUCOSE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK TRANSCRIPTION FACTOR 1; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; OXAMIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYGLUCOSE; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLUCOSE; GLYCOLYSIS; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; LACTIC ACID; OXAMIC ACID; OXYGEN; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 70350564782     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.229     Document Type: Article

References (39)

1. Balinsky D, Platz CE, Lewis JW. (1983). Isozyme patterns of normal, benign, and malignant human breast tissues. Cancer Res 43: 5895-5901.
2. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E et al. (1992). Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95.
3. Chen Z, Lu W, Garcia-Prieto C, Huang P. (2007). The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39: 267-274.
4. Dai C, Whitesell L, Rogers AB, Lindquist S. (2007). Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130: 1005-1018.
5. Dang CV, Semenza GL. (1999). Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72.
6. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
7. Fantin VR, St-Pierre J, Leder P. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425-434.
8. Garber K. (2006). Energy deregulation: licensing tumors to grow. Science 312: 1158-1159.
9. Gatenby RA, Gillies RJ. (2007). Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 39: 1358-1366.
10. Gillies RJ, Robey I, Gatenby RA. (2008). Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49(Suppl 2): 24S-42S.
11. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578-10582.
12. Hsu PP, Sabatini DM. (2008). Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707.
13. Khaleque MA, Bharti A, Gong J, Gray PJ, Sachdev V, Ciocca DR et al. (2008). Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1. Oncogene 27: 1886-1893.
14. Khaleque MA, Bharti A, Sawyer D, Gong J, Benjamin IJ, Stevenson MA et al. (2005). Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth. Oncogene 24: 6564-6573.
15. Kim JW, Dang CV. (2006). Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66: 8927-8930.
16. Kroemer G, Pouyssegur J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482.
17. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. (2001). HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004.
18. Li YM, Zhou BP, Deng J, Pan Y, Hay N, Hung MC. (2005). A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpres-sing cells. Cancer Res 65: 3257-3263.
19. Liu H, Zhou M, Luo X, Zhang L, Niu Z, Peng C et al. (2008). Transcriptional regulation of BRD7 expression by Sp1 and c-Myc. BMC Mol Biol 9: 111-124.
20. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM et al. (2009). Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 15: 1326-1334.
21. Min JN, Huang L, Zimonjic DB, Moskophidis D, Mivechi NF. (2007). Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 26: 5086-5097.
22. Nguyen T, Ogbi M, Johnson JA. (2008). Delta protein kinase C interacts with the d subunit of the F1F0 ATPase in neonatal cardiac myocytes exposed to hypoxia or phorbol ester. Implications for F1F0 ATPase regulation. J Biol Chem 283: 29831-29840.
23. Pelicano H, Martin DS, Xu RH, Huang P. (2006). Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646.
24. Ramanathan A, Wang C, Schreiber SL. (2005). Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 102: 5992-5997.
25. Rutter J, Reick M, Wu LC, McKnight SL. (2001). Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 293: 510-514.
26. Sarge KD, Murphy SP, Morimoto RI. (1993). Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress. Mol Cell Biol 13: 1392-1407.
27. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
28. Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S et al. (2002). Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 9: 993-1004.
29. Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL et al. (2006a). Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 66: 3764-3772.
30. Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y et al. (2005). ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res 65: 1858-1867.
31. Tan M, Li P, Sun M, Yin G, Yu D. (2006b). Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 25: 3286-3295.
32. Tan M, Yao J, Yu D. (1997). Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199-1205.
33. Wadekar SA, Li D, Sanchez ER. (2004). Agonist-activated glucocor-ticoid receptor inhibits binding of heat shock factor 1 to the heat shock protein 70 promoter in vivo. Mol Endocrinol 18: 500-508.
34. Warburg O. (1956). On respiratory impairment in cancer cells. Science 124: 269-270.
35. Westerheide SD, Morimoto RI. (2005). Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem 280: 33097-33100.
36. Yarden Y, Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
37. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R et al. (2007). ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117: 2051-2058.
38. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y et al. (2004). Activation of the Akt/mammalian target of rapamycin/ 4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788.
39. Zu XL, Guppy M. (2004). Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 313: 459-465.